Expression of stemness markers has also been reported in various cancers under therapeutic pressure: JARID1B [67] and CD271 [66] in melanoma; SOX2, SOX4, NFIA, and OLIG2 in glioblastomas [63,64]; stemness gene signature in AML [77]; CD133 and CD44 in breast cancers [73,97,102]; CD24, CD44, CD133, CXCR4, ALDH1A3, higher ALDH activity, and higher sphere-forming ability in colon cancers [69]; CD133, CD44, and ALDH activity in KRAS-ablation of pancreatic cancer models [71]. This evidence concerns the gene CD44 and pancreatic neoplasm.